FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note released on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.36 on Friday. The firm has a market capitalization of $35.54 million, a price-to-earnings ratio of -0.15 and a beta of 0.70. The stock has a 50 day moving average price of $0.39 and a 200 day moving average price of $0.90. FibroGen has a 52-week low of $0.30 and a 52-week high of $2.93.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $50.64 million during the quarter, compared to analysts’ expectations of $33.00 million. During the same quarter in the previous year, the firm posted ($0.65) EPS. Analysts forecast that FibroGen will post -0.91 earnings per share for the current year.

Institutional Trading of FibroGen

A number of hedge funds have recently bought and sold shares of FGEN. Acadian Asset Management LLC lifted its holdings in FibroGen by 34.4% during the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after buying an additional 860,854 shares during the period. AQR Capital Management LLC lifted its holdings in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares during the period. XTX Topco Ltd purchased a new stake in FibroGen during the second quarter worth $424,000. Cubist Systematic Strategies LLC lifted its holdings in FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in FibroGen during the second quarter worth $145,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.